Biogen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 01:30PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director

Great. Good morning, everybody. Thanks for joining us for the next session this morning. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. We're pleased to have Biogen with us this morning and Michel Vounatsos, the CEO; and Alisha Alaimo, who runs Commercial.

Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. And I'm going to turn it over to Michel to make some opening comments, and then we'll get into Q&A.

Michel Vounatsos - Biogen Inc. - CEO & Director

Thank you, Matt, and good morning, everyone. Before I begin, I would like to state that we will be making some forward-looking statements, which contain risks and uncertainties, so I encourage everyone to go to the risk factors discussed in our SEC filing.

Before I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot